Finacea Foam makes $680K for Foamix

finacea-foam-logo

A recent press release from Foamix gives a view into how well Finacea Foam is selling. Based on Q1 2016 sales of the newly approved Finacea Foam, Bayer HealthCare made a royalty payment of $682,000 to Foamix as a fee for licensing their foaming technology.

Along with the comment that Finacea Foam sales are continuing to grow, it seems that Finacea Foam is doing well so far as a product.

There has been little feedback from users of Finacea Foam so far. If you have tried it, do please leave us some comments here – Finacea Foam Reviews.

Foamix Reports First Quarter 2016 Financial Results and Provides Business Update

U.S. Sales of Finacea Foam, azelaic acid 15%, continue to grow. The royalty payment from Bayer HealthCare AG for Finacea Foam for Q1, 2016 was $682,000, up 170% from the fourth quarter of 2015.

Finacea Foam was developed as part of a research and development collaboration between Foamix and Bayer, utilizing Foamix’s proprietary foam technology platform. The drug was launched by Bayer in the USA in September, 2015.

Related Articles

About the Author

About the Author:

David Pascoe started the Rosacea Support Group in October 1998.

.

Follow Rosacea Support

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

Leave a Comment

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.